efficacy

Passage of the Amendment to the Advanced Regenerative Biotech Act a Positive Catalyst for Korean and Japanese Cell Therapy Companies

Source Node:
Time Stamp: February 7, 2024 10:46 AM - Modified On: February 7, 2024 - Published By:
Source Cluster:
Republished By Plato

Legislation Puts Renewed Focus on Next-Generation NK Cell Therapies New York, Feb 7, 2024 - (Plato Data) - On Thursday February 2, 2024, the bio industry welcomed the parliament’s passage of a bill that adds regenerative medicine organizations to the list of those considered for human cell management business licenses. The National Assembly passed the “Amendment to the Act on Safety and Support for Advanced Regenerative Medicine and Advanced Biopharmaceuticals” in a plenary session paving the way for certain next generation NK Cell Therapy companies to recognized as a licensed

NKGen Biotech Advances Alzheimer’s Treatment with SNK01: First Patient Dosed in Phase 1/2a Trial

Source Node:
Time Stamp: December 29, 2023 3:07 AM - Modified On: December 29, 2023 - Published By:
Source Cluster:
Republished By Plato

December 29, 2023 - NKGen Biotech, Inc. (Nasdaq: NKGN) is making strides in Alzheimer's disease (AD) treatment with the dosing of the first patient in its Phase 1/2a trial for SNK01, an autologous natural killer (NK) cell therapy. The innovative product, designed for moderate AD, has demonstrated promising results in neuroinflammation and cognitive function during its Phase 1 safety trial. Key Points: SNK01 Efficacy: NKGen's SNK01, a cryopreserved autologous NK cell therapy, showed improvement in neuroinflammation and cognitive function in the Phase 1 dose-escalation safety trial. The therapy boasts enhanced

Revolutionizing Clinical Trials: The Digital Watermarking and AI Duo

Source Node:
Time Stamp: October 5, 2023 11:22 AM - Modified On: October 5, 2023 - Published By:
Source Cluster:
Republished By Plato

Revolutionizing Clinical Trials: The Digital Watermarking and AI Duo Clinical trials, the linchpin of medical research, have long been riddled with inefficiencies, from patient recruitment bottlenecks to data management hurdles. As a technology and banking analyst, I've seen how digital solutions can overhaul entire sectors, offering improved productivity and streamlined processes. It's high time that clinical trials get a dose of such digital innovation, and there's a potent combination on the horizon: digital watermarking coupled with Artificial Intelligence (AI). At first glance, one might wonder: how can a technique often

GMEX Group launches ZERO13 digital carbon credits aggregation ecosystem

Source Node:
Time Stamp: May 4, 2023 5:58 AM - Modified On: May 4, 2023 - Published By:
Source Cluster:
Republished By Plato

Partners with Verdana Eco-Consortium, Alléo Energy and Pay DIRT London., May. 4, 2023 -- GMEX Group Limited (“GMEX”), a leader in digital business and technology solutions for capital, commodities and sustainability markets, announces the launch of ZERO13, a climate fintech. ZERO13 provides an automated AI and multi-blockchain driven aggregation ecosystem delivering trusted supply, digital issuance, trading, clearing and settlement for a broad range of carbon credits and related ESG real-world assets. ZERO13 digitally interconnects multiple stakeholders, including registries, banks, custodians, asset managers, corporates, buyers and sellers, markets, exchanges, climate tech